Artivion (NYSE:AORT) Releases Quarterly Earnings Results

Artivion (NYSE:AORT) issued its quarterly earnings results on Monday. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.04, Yahoo Finance reports. The firm had revenue of $97.43 million during the quarter, compared to the consensus estimate of $92.30 million. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. During the same quarter last year, the company posted $0.02 EPS. Artivion updated its FY 2024 guidance to EPS.

Artivion Price Performance

Shares of AORT stock traded down $0.44 during trading hours on Wednesday, hitting $23.33. 58,655 shares of the company’s stock were exchanged, compared to its average volume of 219,342. Artivion has a 12-month low of $12.16 and a 12-month high of $25.51. The company has a market capitalization of $961.20 million, a PE ratio of -31.80 and a beta of 1.66. The business’s 50 day simple moving average is $20.48 and its 200-day simple moving average is $18.14. The company has a current ratio of 4.85, a quick ratio of 3.43 and a debt-to-equity ratio of 1.10.

Insider Activity

In other news, VP Andrew M. Green sold 1,462 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $20.00, for a total transaction of $29,240.00. Following the transaction, the vice president now directly owns 41,121 shares of the company’s stock, valued at $822,420. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Rochelle L. Maney sold 2,315 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $20.27, for a total transaction of $46,925.05. Following the completion of the sale, the vice president now directly owns 39,197 shares in the company, valued at $794,523.19. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Andrew M. Green sold 1,462 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $20.00, for a total value of $29,240.00. Following the transaction, the vice president now owns 41,121 shares in the company, valued at approximately $822,420. The disclosure for this sale can be found here. In the last 90 days, insiders sold 149,952 shares of company stock valued at $2,891,627. Corporate insiders own 8.10% of the company’s stock.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of research analyst reports. Needham & Company LLC increased their price target on shares of Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Stifel Nicolaus increased their target price on Artivion from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.